62 related articles for article (PubMed ID: 25104443)
1. Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
Feng FY; Speers C; Liu M; Jackson WC; Moon D; Rinkinen J; Wilder-Romans K; Jagsi R; Pierce LJ
Breast Cancer Res Treat; 2014 Aug; 147(1):81-94. PubMed ID: 25104443
[TBL] [Abstract][Full Text] [Related]
2. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
Chandler BC; Moubadder L; Ritter CL; Liu M; Cameron M; Wilder-Romans K; Zhang A; Pesch AM; Michmerhuizen AR; Hirsh N; Androsiglio M; Ward T; Olsen E; Niknafs YS; Merajver S; Thomas DG; Brown PH; Lawrence TS; Nyati S; Pierce LJ; Chinnaiyan A; Speers C
J Clin Invest; 2020 Feb; 130(2):958-973. PubMed ID: 31961339
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture.
Manda K; Juerß D; Fischer P; Schröder A; Koenen A; Hildebrandt G
Invest New Drugs; 2021 Jun; 39(3):658-669. PubMed ID: 33313978
[TBL] [Abstract][Full Text] [Related]
4. Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.
Li B; Zhao X; Zhang L; Cheng W
Front Oncol; 2020; 10():588533. PubMed ID: 33634018
[TBL] [Abstract][Full Text] [Related]
5. Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator.
Azria D; Brengues M; Gourgou S; Bourgier C
Front Oncol; 2018; 8():83. PubMed ID: 29675397
[TBL] [Abstract][Full Text] [Related]
6. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
7. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
8. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
[TBL] [Abstract][Full Text] [Related]
9. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Alli E; Solow-Cordero D; Casey SC; Ford JM
Cancer Res; 2014 Nov; 74(21):6205-15. PubMed ID: 25217519
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
Gilabert M; Launay S; Ginestier C; Bertucci F; Audebert S; Pophillat M; Toiron Y; Baudelet E; Finetti P; Noguchi T; Sobol H; Birnbaum D; Borg JP; Charafe-Jauffret E; Gonçalves A
PLoS One; 2014; 9(8):e104302. PubMed ID: 25144364
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Byrski T; Huzarski T; Dent R; Marczyk E; Jasiowka M; Gronwald J; Jakubowicz J; Cybulski C; Wisniowski R; Godlewski D; Lubinski J; Narod SA
Breast Cancer Res Treat; 2014 Sep; 147(2):401-5. PubMed ID: 25129345
[TBL] [Abstract][Full Text] [Related]
14. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Michmerhuizen AR; Pesch AM; Moubadder L; Chandler BC; Wilder-Romans K; Cameron M; Olsen E; Thomas DG; Zhang A; Hirsh N; Ritter CL; Liu M; Nyati S; Pierce LJ; Jagsi R; Speers C
Mol Cancer Ther; 2019 Nov; 18(11):2063-2073. PubMed ID: 31413177
[TBL] [Abstract][Full Text] [Related]
15. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y; Liang L; Li Z; Huang Y; Jiang M; Zou B; Xu Y
Front Oncol; 2023; 13():1295579. PubMed ID: 38111536
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors combined with radiotherapy: are we ready?
Sun C; Chu A; Song R; Liu S; Chai T; Wang X; Liu Z
Front Pharmacol; 2023; 14():1234973. PubMed ID: 37954854
[TBL] [Abstract][Full Text] [Related]
17. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.
Jungles KM; Holcomb EA; Pearson AN; Jungles KR; Bishop CR; Pierce LJ; Green MD; Speers CW
Front Oncol; 2022; 12():1022542. PubMed ID: 36387071
[TBL] [Abstract][Full Text] [Related]
18. Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Michmerhuizen AR; Lerner LM; Ward C; Pesch AM; Zhang A; Schwartz R; Wilder-Romans K; Eisner JR; Rae JM; Pierce LJ; Speers CW
Br J Cancer; 2022 Sep; 127(5):927-936. PubMed ID: 35618789
[TBL] [Abstract][Full Text] [Related]
19. Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management.
Beddok A; Cottu P; Fourquet A; Kirova Y
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944978
[TBL] [Abstract][Full Text] [Related]
20. Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Dias MP; Moser SC; Ganesan S; Jonkers J
Nat Rev Clin Oncol; 2021 Dec; 18(12):773-791. PubMed ID: 34285417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
